EUVIMEDEUVIMED entdecken
Crossref

Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin for Muscle-Invasive Bladder Cancer: Real-World Feasibility and Safety in a Resource-Constrained Setting

Deepak Sundriyal iD, Sai Prasath iD, Harsha S Prakash iD, Anusha Mruthyunjaya Swamy iD, Karthik Jayalingappa iD, Mayank Kapoor iD, Mahesh Koulagi iD, Deepa Joseph iD, Sweety Gupta iD, Parmod Kumar iD, Ujjawal Shriwastav iD, Amit Sehrawat iD

JCO Global Oncology · 2026-08 · 12 (8)

DOI: 10.1200/go-26-00219 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2026-08. Verfasst von Deepak Sundriyal und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology Hematology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India. Hauptthemen laut MEDLINE: Cisplatin, Urinary Bladder Neoplasms, Doxorubicin, Methotrexate. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Muscle-invasive bladder carcinoma (MIBC) poses major treatment challenges in low- and middle-income countries because of logistical and socioeconomic barriers limiting neoadjuvant chemotherapy (NAC) delivery. While dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) improves pathologic response and survival over gemcitabine-cisplatin, its multiday schedule reduces practicality. Accelerated MVAC (AMVAC), a single-day outpatient regimen, may offer a feasible alternative. This study evaluated the feasibility and safety of AMVAC in Indian patients with MIBC. METHODS We conducted a single-arm feasibility study at the All India Institute of Medical Sciences, Rishikesh, India, between December 2021 and November 2024. Adults with stage II-III MIBC and cisplatin eligibility received 3-4 cycles of single-day AMVAC with pegfilgrastim support before radical cystectomy. Feasibility was defined as completion of ≥3 or 4 cycles within protocol-specified timeframes. Toxicities were graded using CTCAE v5.0, and outcomes were analyzed descriptively. RESULTS Sixty patients were enrolled (mean age 55.2 ± 11.2 years; 90% male); 55 received neoadjuvant, and five adjuvant therapy. The mean number of chemotherapy cycles delivered was 3.87 ± 0.85. Feasibility outcomes were favorable, with 91.6% completing three and 76.6% completing four cycles within protocol timelines. Dose reductions for grade ≥3 toxicities were required in 13 patients (21.7%), whereas four patients discontinued treatment because of reduced creatinine clearance. Grade 3 adverse events occurred in 38.3%, most commonly anemia (16.7%), fatigue, and mucositis (13.3% each). Among neoadjuvant recipients undergoing cystectomy (n = 40), pathologic complete response (PCR) was achieved in 32.5% and pathologic downstaging was achieved in 55%. CONCLUSION Single-day AMVAC is a feasible and tolerable NAC regimen in a resource-constrained setting, with encouraging PCR and manageable toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinUrinary Bladder NeoplasmsDoxorubicinMethotrexateVinblastineAntineoplastic Combined Chemotherapy ProtocolsHumansMaleMiddle AgedFemaleFeasibility StudiesAgedAdultResource-Limited SettingsNeoadjuvant TherapyIndia

Substanzen

CisplatinDoxorubicinMethotrexateVinblastine

Autor:innen und Institutionen

  • Department of Medical Oncology Hematology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
  • Department of Radiation Oncology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
  • Department of Medical Oncology Hematology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
  • Department of Medicine, Chitwan Medical College, Bharatpur, Nepal.

ORCID-Profile: Deepak Sundriyal, Sai Prasath, Harsha S Prakash, Anusha Mruthyunjaya Swamy, Karthik Jayalingappa, Mayank Kapoor, Mahesh Koulagi, Deepa Joseph, Sweety Gupta, Parmod Kumar, Ujjawal Shriwastav, Amit Sehrawat

Zitieren

APA

Sundriyal, D., Prasath, S., Prakash, H. S., Swamy, A. M., Jayalingappa, K., Kapoor, M., Koulagi, M., Joseph, D., Gupta, S., Kumar, P., Shriwastav, U., & Sehrawat, A. (2026). Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin for Muscle-Invasive Bladder Cancer: Real-World Feasibility and Safety in a Resource-Constrained Setting. JCO Global Oncology, 12(8). https://doi.org/10.1200/go-26-00219

Vancouver

Sundriyal D, Prasath S, Prakash HS, Swamy AM, Jayalingappa K, Kapoor M, et al. Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin for Muscle-Invasive Bladder Cancer: Real-World Feasibility and Safety in a Resource-Constrained Setting. JCO Global Oncology. 2026;12(8). doi:10.1200/go-26-00219

BibTeX
@article{Sundriyal2026,
  author = {Sundriyal, Deepak and Prasath, Sai and Prakash, Harsha S and Swamy, Anusha Mruthyunjaya and Jayalingappa, Karthik and Kapoor, Mayank and Koulagi, Mahesh and Joseph, Deepa and Gupta, Sweety and Kumar, Parmod and Shriwastav, Ujjawal and Sehrawat, Amit},
  title = {Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin for Muscle-Invasive Bladder Cancer: Real-World Feasibility and Safety in a Resource-Constrained Setting},
  journal = {JCO Global Oncology},
  year = {2026},
  volume = {12},
  number = {8},
  doi = {10.1200/go-26-00219}
}
Kostenlos starten →